S-3,4-methylenedioxymethamphetamine

Phase 1Small molecule

UUniversity Hospital, Basel, Switzerland

S-3,4-methylenedioxymethamphetamine is one of 10 small molecule programs targeting Acute. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AcuteCompleted

AcutePhase 1

Completed

Competition

Competitive Landscape

11 competitors in Acute

#DrugCompanyPhaseTrials

Fetroja

Shionogi

Approved

1 2

Orencia

Bristol-Myers Squibb

Phase 2

1 3

Vyvgart

Argenx

Phase 2

1 4

Dapansutrile

OOlatec Therapeutics LLC

Phase 3

1 5

Clemastine Fumarate

Novartis

Phase 2

1 6

Resotran

Takeda

Preclinical

1 7

Gen-1124

GGEn1E Lifesciences

Phase 2

1 8

Nicotine Pouches

JJohns Hopkins University

Phase 1

1 9

S-3,4-methylenedioxymethamphetamine

UUniversity Hospital, Basel, Switzerland

Phase 1

2 10

R-3,4-Methylenedioxymethamphetamine

UUniversity Hospital, Basel, Switzerland

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Acute

NCT06905652

Clinical

Trials by Indication[1]

Acute2 trials

Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT06905652·24 enrolled

Acute Effects of R- and S-MDMA in Healthy Subjects

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT05277636·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for S-3,4-methylenedioxymethamphetamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S-3,4-methylenedioxymethamphetamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S-3,4-methylenedioxymethamphetamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospital, Basel, Switzerland

S-3,4-methylenedioxymethamphetamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Acute2 trials

References

Drug Info

Quick Facts

Related News